Literature DB >> 10644351

Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.

Y Maeda1, M Foda, S Matsushita, S Harada.   

Abstract

To determine whether C-C chemokines play an important role in the phenotype switch of human immunodeficiency virus (HIV) from CCR5 to CXCR4 usage during the course of an infection in vivo, macrophage inflammatory protein (MIP)-1alpha-resistant variants were isolated from CCR5-tropic (R5) HIV-1 in vitro. The selected variants displayed reduced sensitivities to MIP-1alpha (fourfold) through CCR5-expressing CD4-HeLa/long terminal repeat-beta-galactosidase (MAGI/CCR5) cells. The variants were also resistant to other natural ligands for CCR5, namely, MIP-1beta (>4-fold) and RANTES (regulated upon activation, normal T-cell expressed and secreted) (6-fold). The env sequence analyses revealed that the variants had amino acid substitutions in V2 (valine 166 to methionine) and V3 (serine 303 to glycine), although the same V3 substitution appeared in virus passaged without MIP-1alpha. A single-round replication assay using a luciferase reporter HIV-1 strain pseudotyped with mutant envelopes confirmed that mutations in both V2 and V3 were necessary to confer the reduced sensitivity to MIP-1alpha, MIP-1beta, and RANTES. However, the double mutant did not switch its chemokine receptor usage from CCR5 to CXCR4, indicating the altered recognition of CCR5 by this mutant. These results indicated that V2 combined with the V3 region of the CCR5-tropic HIV-1 envelope modulates the sensitivity of HIV-1 to C-C chemokines without altering the ability to use chemokine receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644351      PMCID: PMC111656          DOI: 10.1128/jvi.74.4.1787-1793.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  A cDNA clone inducible in human tonsillar lymphocytes by a tumor promoter codes for a novel protein of the beta-thromboglobulin superfamily.

Authors:  K Obaru; T Hattori; Y Yamamura; K Takatsuki; H Nomiyama; S Maeda; K Shimada
Journal:  Mol Immunol       Date:  1989-04       Impact factor: 4.407

3.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

4.  A cDNA clone used to study mRNA inducible in human tonsillar lymphocytes by a tumor promoter.

Authors:  K Obaru; M Fukuda; S Maeda; K Shimada
Journal:  J Biochem       Date:  1986-03       Impact factor: 3.387

5.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

Authors:  S S Hwang; T J Boyle; H K Lyerly; B R Cullen
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

8.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism.

Authors:  B Chesebro; K Wehrly; J Nishio; S Perryman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

10.  Biologic features of HIV-1 that correlate with virulence in the host.

Authors:  C Cheng-Mayer; D Seto; M Tateno; J A Levy
Journal:  Science       Date:  1988-04-01       Impact factor: 47.728

View more
  24 in total

1.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

Authors:  Masanori Baba; Hiroshi Miyake; Xin Wang; Mika Okamoto; Katsunori Takashima
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.

Authors:  Kenji Maeda; Debananda Das; Philip D Yin; Kiyoto Tsuchiya; Hiromi Ogata-Aoki; Hirotomo Nakata; Rachael B Norman; Lauren A Hackney; Yoshikazu Takaoka; Hiroaki Mitsuya
Journal:  J Mol Biol       Date:  2008-06-20       Impact factor: 5.469

5.  Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.

Authors:  Debananda Das; Kenji Maeda; Yasuhiro Hayashi; Navnath Gavande; Darshan V Desai; Simon B Chang; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

6.  Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.

Authors:  Katsunori Takashima; Hiroshi Miyake; Naoyuki Kanzaki; Yoshihiko Tagawa; Xin Wang; Yoshihiro Sugihara; Yuji Iizawa; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Human T-cell leukemia virus type-I (HTLV-I) tax is not the only one factor to enhance human immunodeficiency virus type-I (HIV-1) infection in culture-supernatants.

Authors:  A Tempaku; Y Maeda; W Song; S Harada
Journal:  Virus Genes       Date:  2001       Impact factor: 2.332

8.  Separate cellular localizations of human T-lymphotropic virus 1 (HTLV-1) Env and glucose transporter type 1 (GLUT1) are required for HTLV-1 Env-mediated fusion and infection.

Authors:  Yosuke Maeda; Hiromi Terasawa; Yuetsu Tanaka; Chisho Mitsuura; Kaori Nakashima; Keisuke Yusa; Shinji Harada
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

9.  Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.

Authors:  Yosuke Maeda; Taichiro Takemura; Takayuki Chikata; Takeo Kuwata; Hiromi Terasawa; Riito Fujimoto; Nozomi Kuse; Tomohiro Akahoshi; Hayato Murakoshi; Giang Van Tran; Yu Zhang; Chau Ha Pham; Anh Hong Quynh Pham; Kazuaki Monde; Tomohiro Sawa; Shuzo Matsushita; Trung Vu Nguyen; Kinh Van Nguyen; Futoshi Hasebe; Tetsu Yamashiro; Masafumi Takiguchi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

10.  The entry of entry inhibitors: a fusion of science and medicine.

Authors:  John P Moore; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.